Collectively, these findings implicate HexA-driven GM3 accumulation in microglia as a key contributor to impaired Aβ clearance and heightened neuroinflammation in AD, highlighting HexA as a potential therapeutic target for restoring microglial function and mitigating disease progression. Here, HEXA is linked to Alzheimer disease.